Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose is to assess the response of subjects to etanercept (as compared to placebo) in
treating the physical signs of mucosal and cutaneous lichen planus. The investigators also
wish to assess the effect of etanercept on disease-related itching, pain, and serious adverse
events in patients with lichen planus.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University Wake Forest University
Collaborators:
Emory University Fivenson, David, M.D. Icahn School of Medicine at Mount Sinai Oregon Health and Science University The Cleveland Clinic Tufts Medical Center University Hospitals Cleveland Medical Center University of Louisville University of Michigan Wake Forest University Health Sciences Wright State University